Who Paid My Doc
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E
Research payments
$2,542,053
Through program year 2025, $2,542,053 in research payments was reported against A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E, across 337 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $2,098,021 | 302 |
| 2024 | Research | $444,032 | 35 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Kiran Farheen Katy, TX Named on 23 payments
- Alexander Hu Flagstaff, AZ Named on 18 payments
- Swati Bharadwaj Phoenix, AZ Named on 18 payments
- Diraj Karnani Apple Valley, CA Named on 15 payments
- Roel Querubin Marietta, GA Named on 14 payments
- Amal Mehta Riverside, CA Named on 14 payments
- Jawad Bilal Tucson, AZ Named on 13 payments
- Rodney Daniel Boca Raton, FL Named on 13 payments
- Shirley Pang Fullerton, CA Named on 12 payments
- Vishala Chindalore Anniston, AL Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.